MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Amgen P/E Ratio 2011-2026 | AMGN
Annual P/E Ratio Amgen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.7 | 38.3 | 23.1 | 19.7 | 21.5 | 17.3 | 17.4 | 14.6 | 70.7 | 15 | 16.7 | 22.4 | 17.9 | 15.2 | 16.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70.7 | 14.6 | 23.5 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-2.15 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-0.183 | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
1.35 | $ 1.45 | -7.94 % | $ 170 M |  USA |
 |
AgeX Therapeutics
AGE
|
5.53 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-6.15 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Compugen Ltd.
CGEN
|
5.55 | $ 2.1 | -5.41 % | $ 196 M |  Israel |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-10.5 | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-25.1 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
16.3 | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
-19.4 | $ 88.08 | -1.69 % | $ 21.3 B | Germany |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-0.0167 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-18.5 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-581 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-0.403 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-251 | - | -18.52 % | $ 27.3 M | Britain |
 |
CRISPR Therapeutics AG
CRSP
|
-7.54 | $ 51.84 | -8.97 % | $ 4.66 B |  Schweiz |
 |
Affimed N.V.
AFMD
|
-9.16 | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.859 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-0.259 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-1.19 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-7.88 | $ 28.62 | -4.38 % | $ 1.9 B | USA |
 |
Generation Bio Co.
GBIO
|
-1.41 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-0.18 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.12 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
0.00975 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-2.93 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-4.4 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-19.7 | $ 14.48 | -2.1 % | $ 208 M | USA |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.964 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.735 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 3.09 | -2.22 % | $ 5.09 M | Israel |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-16.1 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-213 | $ 21.23 | -3.28 % | $ 2.7 B | USA |